HMBD-002
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HMBD-002, covering 2025-10-16 to 2025-10-16. Get the full timeline:
Most recent: Clinical Trial Update: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors [Phase 1]